Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 27Active not recruiting 26Not yet recruiting 3Completed 3Suspended 2Terminated 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Down Syndrome 1

Interventions

pembrolizumab 26Cisplatin 14Nivolumab 11Cyclophosphamide 11Carboplatin 11Paclitaxel 9Docetaxel 9Radiotherapy, Intensity-Modulated 8Radiotherapy 8Magnetic Resonance Spectroscopy 8Radiosurgery 7Radiation 7Fluorouracil 7Bevacizumab 7Leucovorin 6Irinotecan 6Gemcitabine 6Doxorubicin 6venetoclax 5olaparib 5enzalutamide 5Prednisone 5Pemetrexed 5Oxaliplatin 5Metformin 5Azacitidine 5fludarabine 4atezolizumab 4Taxes 4Surveys and Questionnaires 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Vincristine × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03274492 2026-05-08

POLARIX

Hoffmann-La Roche

Phase 3 Completed
1,000 enrolled 1 FDA
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡